Skip to content

Clinical study of Mai-Zhi-Ling tablet in the treatment of postthrombotic syndrome of lower extremity deep vein

Clinical study of Mai-Zhi-Ling tablet in the treatment of postthrombotic syndrome of lower extremity deep vein

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032201
Enrollment
Unknown
Registered
2020-04-22
Start date
2018-12-20
Completion date
Unknown
Last updated
2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postthrombotic syndrome of deep vein in lower extremity

Interventions

Experimental group:Conventional anticoagulant therapy, wearing 20-30mmHg elastic socks for 6 months plus oral Mai-Zhi-Ling tablet
Control group:Conventional anticoagulant therapy, wearing 20-30mmHg elastic socks for 6 months

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. in the diagnosis of lower extremity venous imaging and color doppler ultrasound diagnosis of DVT; 2. was first diagnosed with DVT in patients with chronic phase and the PTS for Villalta score; 3. patients with mild and moderate) by color doppler ultrasound examination or angiography confirmed with venous reflux disorder; 4. always without limbs swelling performance, such as eliminate recurrence patients with DVT; 5. good adherence

Exclusion criteria

Exclusion criteria: 1. primary lower extremity deep vein valve insufficiency and patients with congenital vascular malformation; 2. people with blood coagulation dysfunction; 3. pregnant and lactation women's; 4. cancer patients complicated with DVT; 5. on the patients with severe drug reaction; 6. with severe stomach disease patients; 7. patients treated with other intravenous active pharmaceutical medicine within past one month; 8. uncontrolled systemic diseases such as diabetes, high blood pressure, heart disease; 9. patients unable to be site visit.

Design outcomes

Primary

MeasureTime frame
villalta scores;

Secondary

MeasureTime frame
Change of symptoms include limb edema, swelling pain, abnormal skin color, limb heaviness, skin temperature, eczema and ulcer, and D- dimer numerical changes;

Countries

China

Contacts

Public ContactZhu Guoxian

Shenzhen Second People's Hospital

13823359885@163.com+86 13823359885

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026